Cronos Group(CRON) - 2025 Q2 - Quarterly Results

Executive Summary & Highlights This section provides an overview of Cronos Group's strong Q2 2025 financial and operational performance, highlighting key achievements and strategic developments Q2 2025 Performance Highlights Cronos Group reported strong Q2 2025 performance with 21% net revenue growth, record international sales, and a robust balance sheet supporting global expansion - Net revenue increased by 21% in Q2 2025[1] - PEACE NATURALS® maintained its number one position in Israel, achieving record international and Israeli market revenues[1][2] - The balance sheet remained strong with $834 million in cash and short-term investments[1][3] - In the Canadian market, Spinach® ranked second overall (4.7% market share) and third in flower brands (4.9% market share), with its gummies among the top ten edibles (19.9% market share) and vapes ranking fourth (6.5% market share), including the second-ranked 1.2g vape cartridge (8.4% market share)[10] - Lord Jones® Chocolate Fusions™ held a 10.2% market share, making it the third best-selling chocolate cannabis edible brand in Canada, and ranked first in the hash-infused pre-roll segment with a 28.5% market share[11] - The Cronos GrowCo expansion is complete, with sales expected to commence in Fall 2025, driving growth in both international and Canadian domestic markets[3][14] Consolidated Financial Results This section details Cronos Group's Q2 2025 consolidated financial performance, including net revenue, gross profit, net loss, and adjusted EBITDA Overview of Q2 2025 Financial Performance Cronos Group's Q2 2025 consolidated net revenue grew 21% to $33.5 million, with gross profit surging 130% to $14.5 million, despite a net loss increase to $38.5 million due to unrealized foreign exchange losses - The company obtained majority control of Cronos GrowCo and began consolidating its results effective July 1, 2024[4] Key Financial Data for Q2 2025 (Compared to Q2 2024) | Metric | Q2 2025 (Thousand Dollars) | Q2 2024 (Thousand Dollars) | Change ($) | Change (%) | | :-------------------------------- | :---------------------- | :---------------------- | :--------- | :--------- | | Net Revenue (Total) | 33,455 | 27,762 | 5,693 | 21 % | | Cronos GrowCo Net Revenue Contribution | 2,211 | — | 2,211 | N/A | | Cost of Sales | 18,865 | 21,070 | (2,205) | (10) % | | Inventory Write-downs | 86 | 395 | (309) | (78) % | | Gross Profit | 14,504 | 6,297 | 8,207 | 130 % | | Gross Margin | 43 % | 23 % | N/A | 20 pp | | Adjusted Gross Profit | 14,504 | 6,297 | 8,207 | 130 % | | Adjusted Gross Margin | 43 % | 23 % | N/A | 20 pp | | Net Loss | (38,482) | (8,759) | (29,723) | (339) % | | Adjusted EBITDA | 1,688 | (11,051) | 12,739 | N/M | | Cash and Cash Equivalents (End of Period) | 794,416 | 848,189 | (53,773) | (6) % | | Short-term Investments (End of Period) | 40,000 | — | 40,000 | N/A | | Capital Expenditures | 3,838 | 916 | 2,922 | 319 % | - Net revenue growth was primarily driven by increased cannabis flower sales in Israel and other international markets (excise tax-free), the consolidation of Cronos GrowCo (contributing $2.2 million), and higher cannabis extract sales in the Canadian market[9] - Gross profit growth was mainly attributed to the consolidation of Cronos GrowCo, higher average selling prices from a shift in sales mix towards Israel and other international markets, increased sales volume, and improved production efficiencies[9] - The increase in net loss was primarily due to unrealized foreign exchange losses on U.S. dollar-denominated cash and short-term investments held in Canada (impacted by a stronger Canadian dollar against the U.S. dollar), partially offset by higher gross profit and lower operating expenses[13] - Adjusted EBITDA improved mainly due to increased revenue, lower cost of sales (due to Cronos GrowCo consolidation), and reduced operating expenses (driven by lower general and administrative expenses)[13] Business Updates This section provides updates on Cronos Group's brand and product portfolio performance, as well as the progress of the Cronos GrowCo expansion Brand and Product Portfolio Cronos Group's brand portfolio performed strongly in Q2 2025, with Spinach® maintaining leadership in Canada, Lord Jones® excelling in premium segments, and PEACE NATURALS® achieving record international sales Spinach® Spinach® maintained its strong position in the Canadian market in Q2 2025, ranking second overall (4.7% market share) and third in flower brands (4.9% market share) despite flower supply constraints Spinach® Brand Canadian Market Share and Ranking (Q2 2025) | Brand/Category | Market Share | Ranking | | :------------- | :----------- | :------ | | Spinach® (Overall) | 4.7% | 2 | | Spinach® (Flower) | 4.9% | 3 | | Spinach® Gummies (Edibles) | 19.9% | 5 products in top 10 | | Spinach® (Vape Category) | 6.5% | 4 | | Spinach® Vape Cartridges | 8.4% | 2 | | Spinach® Pink Lemonade 1.2g Vape Cartridge | N/A | Best-selling 1.2g vape cartridge | - The team is strategically allocating inventory and preparing to unlock significant additional capacity through the Cronos GrowCo expansion in Fall 2025[10] Lord Jones® Lord Jones® Chocolate Fusions™ was the third best-selling chocolate cannabis edible brand in Canada in Q2 2025 with a 10.2% market share, and the brand ranked first in the hash-infused pre-roll segment with a 28.5% market share Lord Jones® Brand Canadian Market Share and Ranking (Q2 2025) | Brand/Category | Market Share | Ranking | | :-------------------------- | :----------- | :------ | | Lord Jones® Chocolate Fusions™ | 10.2% | 3 Best-selling Chocolate Edible Brand | | Lord Jones® (Hash-infused Pre-rolls) | 28.5% | 1 | - Launched Lord Jones® Live Resin Caviar, featuring prominent strains like Gorilla Grape and Orange Velvet, reinforcing its premium positioning in the extract category[11] PEACE NATURALS® PEACE NATURALS® continued its strong performance in Israel in Q2 2025, achieving record revenue and sales volume, and successfully expanded into new international medical cannabis markets - In Israel, PEACE NATURALS® was the best-performing brand, achieving record revenue and sales volume in Q2 2025[12] - The PEACE NATURALS® brand launched in the Australian and Maltese medical cannabis markets in Q2 2025, and entered the Swiss medical market subsequent to the quarter end[14] - The company's medical brands have expanded to seven global markets, including Canada, Israel, Germany, the U.K., Australia, Switzerland, and Malta[14] Cronos GrowCo Expansion Cronos GrowCo's expansion project is complete, with sales anticipated to commence in Fall 2025, providing additional supply for international and Canadian domestic market growth - The Cronos GrowCo expansion is complete[14] - Sales are expected to commence in Fall 2025, driving growth in both international and Canadian domestic markets[14] Corporate Developments This section outlines recent corporate developments, including updates on the Israeli anti-dumping duty proposal, strategic investments, and key appointments Proposed Anti-Dumping Duty in Israel: Update Israel's Ministry of Justice confirmed the Finance Minister's rejection of a 165% anti-dumping duty proposal on Canadian medical cannabis imports, a decision welcomed by Cronos Group - Israel's Ministry of Justice announced on July 3, 2025, that the Finance Minister's rejection of the proposed 165% anti-dumping duty on the company's medical cannabis imports was effective[15] - The company strongly refuted the allegations and expressed satisfaction with the decision to reject the anti-dumping duty proposal[15] Investments In July 2025, Cronos invested CAD $25.2 million (approximately USD $18.5 million) in High Tide Inc. via a five-year subordinated secured convertible loan to maintain market competitiveness - In July 2025, Cronos invested CAD $25.2 million (approximately USD $18.5 million) in High Tide Inc., operator of Canna Cabana, Canada's largest cannabis retailer[16] - The investment is structured as a five-year subordinated secured convertible loan with a face value of CAD $30 million (approximately USD $22.1 million), including a 16% original issue discount, bearing an annual interest rate of 4% (paid quarterly in cash), convertible into High Tide common shares (at a conversion price of CAD $4.20 per share, subject to mutual agreement)[16] - Concurrently, the company received a five-year common share purchase warrant exercisable for up to 3,836,317 High Tide common shares at an exercise price of CAD $3.91 per share[16] - This investment helps maintain competition in the cannabis market and ensures Cronos brands remain competitive in Canada[16] Appointments Lloyd Wilson was appointed Chief Accounting Officer of Cronos Group on August 7, 2025, bringing over two decades of financial reporting and operational finance experience - Lloyd Wilson was appointed as the company's Chief Accounting Officer effective August 7, 2025[17] - Lloyd Wilson is a Chartered Professional Accountant with over 20 years of experience in financial reporting, internal audit, plant control, and operational finance, with a strong background in the consumer packaged goods industry[17] Conference Call Cronos Group held a conference call and live webcast on August 7, 2025, to discuss its Q2 2025 business results, with an archived replay available on the company's website - The company held a conference call and live audio webcast on August 7, 2025, at 8:30 a.m. EDT, to discuss its Q2 2025 business results[18] - An audio replay of the conference call has been archived on the company's website[18] Company Overview This section provides a brief overview of Cronos Group, highlighting its mission as an innovative global cannabinoid company focused on research, technology, and brand development About Cronos Group Cronos Group is an innovative global cannabinoid company focused on building disruptive intellectual property through cannabis research, technology, and product development - Cronos is an innovative global cannabinoid company dedicated to building disruptive intellectual property through advancing cannabis research, technology, and product development[20] - The company aims to responsibly elevate consumer experiences and is building an iconic brand portfolio[20] - Cronos' international brand portfolio includes Spinach®, PEACE NATURALS®, and Lord Jones®[20] Forward-Looking Statements This section outlines the nature and scope of forward-looking statements, which are based on current expectations and involve inherent risks and uncertainties that may cause actual results to differ materially Nature and Scope of Forward-Looking Statements This section clarifies the nature of forward-looking statements, which are based on current internal expectations, estimates, forecasts, assumptions, and beliefs, and are not historical facts - Forward-looking statements are based on the company's current internal expectations, estimates, forecasts, assumptions, and beliefs, and are not historical facts[21] - Topics covered by forward-looking statements include: the impact of the Israeli anti-dumping investigation, the Middle East conflict's effect on Israeli operations, expectations for the PEACE NATURALS® brand in Germany, Australia, the U.K., Switzerland, and Malta, cost reduction initiatives (including the cessation of operations at the Winnipeg facility), future plans following the exit from the U.S. hemp-derived cannabinoid product business, the Cronos GrowCo transaction and facility expansion, and expectations for revenue, expenses, gross margin, and capital expenditures[22][25] - Forward-looking statements are based on certain material assumptions management believes are reasonable, but there is no guarantee that these expectations will be achieved[24][26] - Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those stated, with risk factors discussed in the company's reports filed with the SEC and other regulatory authorities[27][28] - Readers should carefully consider these factors and not place undue reliance on forward-looking statements, as the company undertakes no obligation to update or revise any such statements[29] Condensed Consolidated Financial Statements This section presents Cronos Group's condensed consolidated financial statements, including balance sheets, statements of net loss and comprehensive income (loss), and cash flow statements Condensed Consolidated Balance Sheets As of June 30, 2025, total assets slightly increased to $1.175 billion, total liabilities decreased to $45 million, and total shareholders' equity rose to $1.130 billion Condensed Consolidated Balance Sheet Highlights (Thousand Dollars) | Metric | As of June 30, 2025 | As of December 31, 2024 | Change ($) | Change (%) | | :-------------------------- | :------------------ | :----------------- | :--------- | :--------- | | Total Assets | 1,175,227 | 1,166,312 | 8,915 | 0.8 % | | Cash and Cash Equivalents | 794,416 | 858,805 | (64,389) | (7.5) % | | Short-term Investments | 40,000 | — | 40,000 | N/A | | Accounts Receivable, Net | 26,619 | 15,462 | 11,157 | 72.1 % | | Inventory, Net | 42,142 | 33,149 | 8,993 | 27.1 % | | Total Current Assets | 927,147 | 936,113 | (8,966) | (1.0) % | | Total Liabilities | 45,021 | 55,330 | (10,309) | (18.6) % | | Total Shareholders' Equity | 1,130,206 | 1,110,982 | 19,224 | 1.7 % | Condensed Consolidated Statements of Net Loss and Comprehensive Income (Loss) In Q2 2025, net revenue grew 21% to $33.5 million, and gross profit surged 130% to $14.5 million, despite a net loss of $38.5 million primarily due to significant foreign exchange losses Condensed Consolidated Statements of Net Loss and Comprehensive Income (Loss) Highlights (Thousand Dollars) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change ($) | Change (%) | | :----------------------------------- | :------------------------------- | :------------------------------- | :--------- | :--------- | | Net Revenue | 33,455 | 27,762 | 5,693 | 21 % | | Cost of Sales | 18,865 | 21,070 | (2,205) | (10) % | | Gross Profit | 14,504 | 6,297 | 8,207 | 130 % | | Total Operating Expenses | 19,828 | 21,858 | (2,030) | (9) % | | Operating Loss | (5,324) | (15,561) | 10,237 | 65.8 % | | Foreign Currency Gain (Loss) | (39,538) | 6,543 | (46,081) | (704) % | | Net Loss | (38,482) | (8,759) | (29,723) | (339) % | | Basic Net Loss Attributable to Cronos Group | (0.10) | (0.02) | (0.08) | (400) % | Condensed Consolidated Cash Flow Statements For the six months ended June 30, 2025, net cash from operating activities improved to $0.722 million, with investing activities resulting in a $56.3 million net outflow and financing activities using $10.6 million Condensed Consolidated Cash Flow Statement Highlights (Six Months Ended June 30, 2025, Thousand Dollars) | Metric | 2025 | 2024 | Change ($) | Change (%) | | :-------------------------------------- | :----- | :----- | :--------- | :--------- | | Net Cash Provided by (Used in) Operating Activities | 722 | (460) | 1,182 | N/M | | Net Cash Provided by (Used in) Investing Activities | (56,339) | 180,999 | (237,338) | (131) % | | Net Cash Used in Financing Activities | (10,616) | (905) | (9,711) | (1073) % | | Net Change in Cash and Cash Equivalents | (64,389) | 178,898 | (243,287) | (136) % | | Cash and Cash Equivalents, End of Period | 794,416 | 848,189 | (53,773) | (6) % | - Major cash outflows from investing activities included the purchase of short-term investments ($40 million) and property, plant, and equipment ($19.1 million)[33] - Major cash outflows from financing activities included the repurchase of common shares ($3.6 million) and dividends paid to non-controlling interests ($3.9 million)[33] Non-GAAP Financial Measures This section explains Cronos Group's use of non-GAAP financial measures, such as Adjusted EBITDA and Adjusted Gross Profit, to provide additional insights into operational performance Overview of Non-GAAP Measures Cronos Group utilizes non-GAAP measures like Adjusted EBITDA and Adjusted Gross Profit to provide additional insights into operational performance by excluding non-cash and non-recurring items - Non-GAAP measures are intended to supplement U.S. GAAP measures, providing management with additional information on operating results and a better understanding of underlying business trends and results[34][36][43] - All non-GAAP measures have been reconciled to their most directly comparable U.S. GAAP measures[34] Adjusted EBITDA Adjusted EBITDA significantly improved to $1.7 million in Q2 2025 and $4.0 million for the six months ended June 30, 2025, driven by increased revenue and reduced operating expenses - Adjusted EBITDA is defined as net income (loss) excluding interest, taxes (benefit), depreciation, and amortization, adjusted for non-cash items and items not reflective of management's assessment of ongoing business performance[35] Adjusted EBITDA Performance (Thousand Dollars) | Period | 2025 | 2024 | Change ($) | Change (%) | | :-------------------------------- | :----- | :----- | :--------- | :--------- | | Three Months Ended June 30 | 1,688 | (11,051) | 12,739 | N/M | | Six Months Ended June 30 | 3,977 | (21,720) | 25,697 | N/M | - The improvement in Adjusted EBITDA is primarily attributed to increased revenue, lower cost of sales (due to Cronos GrowCo consolidation), and reduced operating expenses (driven by lower general and administrative expenses)[13][40] Adjusted Gross Profit and Adjusted Gross Margin Adjusted gross profit surged 130% to $14.5 million in Q2 2025 and 167% to $28.8 million for the six months ended June 30, 2025, primarily due to Cronos GrowCo consolidation, improved sales mix, and production efficiencies - Adjusted gross profit and adjusted gross margin are non-GAAP measures that exclude the impact of inventory-related purchase accounting adjustments resulting from the Cronos GrowCo transaction[42] Adjusted Gross Profit Performance (Thousand Dollars) | Period | 2025 | 2024 | Change ($) | Change (%) | | :-------------------------------- | :----- | :----- | :--------- | :--------- | | Three Months Ended June 30 | 14,504 | 6,297 | 8,207 | 130 % | | Six Months Ended June 30 | 28,755 | 10,780 | 17,975 | 167 % | Adjusted Gross Margin Performance | Period | 2025 | 2024 | Change (pp) | | :-------------------------------- | :----- | :----- | :---------- | | Three Months Ended June 30 | 43 % | 23 % | 20 pp | | Six Months Ended June 30 | 44 % | 20 % | 24 pp | - Growth is primarily attributed to the consolidation of Cronos GrowCo, higher average selling prices from a shift in sales mix towards Israel and other international markets, increased sales volume, and improved production efficiencies[9][44] Constant Currency Analysis This section provides an analysis of Cronos Group's financial performance on a constant currency basis, isolating the impact of foreign exchange fluctuations Overview of Constant Currency Measures Cronos Group provides constant currency adjusted financial metrics to eliminate the impact of foreign exchange fluctuations on performance, thereby assessing the company's underlying operational performance - Constant currency information is provided to offer a framework for assessing the company's underlying operating performance by excluding the impact of foreign exchange rate fluctuations[45] - Income statement results are translated using the average exchange rates from the comparative period (2024); balance sheet information is translated using the spot exchange rates at the end of the prior year[45] Net Revenue (Constant Currency) On a constant currency basis, Q2 2025 net revenue grew 20% to $33.3 million, and for the six months ended June 30, 2025, it increased 26% to $67.0 million, primarily due to increased international cannabis flower sales and Cronos GrowCo consolidation Net Revenue (Constant Currency, Thousand Dollars) | Period | 2025 | 2024 | Change ($) | Change (%) | | :-------------------------------- | :----- | :----- | :--------- | :--------- | | Three Months Ended June 30 | 33,334 | 27,762 | 5,572 | 20 % | | Six Months Ended June 30 | 66,956 | 53,050 | 13,906 | 26 % | Net Revenue by Product Type (Constant Currency, Q2 2025 vs Q2 2024, Thousand Dollars) | Product Type | 2025 (Thousand Dollars) | 2024 (Thousand Dollars) | Change ($) | Change (%) | | :------------- | :------------------- | :------------------- | :--------- | :--------- | | Cannabis Flower | 24,820 | 20,661 | 4,159 | 20 % | | Cannabis Extracts | 8,446 | 7,064 | 1,382 | 20 % | Net Revenue by Geography (Constant Currency, Q2 2025 vs Q2 2024, Thousand Dollars) | Region | 2025 (Thousand Dollars) | 2024 (Thousand Dollars) | Change ($) | Change (%) | | :------------- | :------------------- | :------------------- | :--------- | :--------- | | Canada | 19,633 | 19,844 | (211) | (1) % | | Israel | 9,001 | 6,889 | 2,112 | 31 % | | Other International | 4,700 | 1,029 | 3,671 | 357 % | - Net revenue growth is primarily attributed to increased cannabis flower sales in Israel and other international markets, the consolidation of Cronos GrowCo (contributing $2.2 million in Q2 2025 and $5.3 million for the six months), and higher cannabis extract sales in the Canadian market[49] Gross Profit (Constant Currency) On a constant currency basis, Q2 2025 gross profit increased 129% to $14.4 million, and for the six months ended June 30, 2025, it rose 166% to $28.6 million, driven by Cronos GrowCo consolidation and improved sales mix Gross Profit (Constant Currency, Thousand Dollars) | Period | 2025 | 2024 | Change ($) | Change (%) | | :-------------------------------- | :----- | :----- | :--------- | :--------- | | Three Months Ended June 30 | 14,421 | 6,297 | 8,124 | 129 % | | Six Months Ended June 30 | 28,645 | 10,780 | 17,865 | 166 % | - Gross profit growth is primarily attributed to the consolidation of Cronos GrowCo, higher average selling prices from a shift in sales mix towards Israel and other international markets, increased sales volume, and improved production efficiencies[50] Operating Expenses (Constant Currency) On a constant currency basis, Q2 2025 operating expenses decreased 9% to $19.8 million, and for the six months ended June 30, 2025, they fell 9% to $38.3 million, primarily due to reduced compensation and equity-based compensation Operating Expenses (Constant Currency, Thousand Dollars) | Period | 2025 | 2024 | Change ($) | Change (%) | | :-------------------------------- | :----- | :----- | :--------- | :--------- | | Three Months Ended June 30 | 19,843 | 21,858 | (2,015) | (9) % | | Six Months Ended June 30 | 38,319 | 42,289 | (3,970) | (9) % | - The decrease in operating expenses is primarily due to lower compensation and benefits, an increase in the prior period expected credit loss provision, and lower equity-based compensation expense[51] - This was partially offset by increased sales and marketing expenses, restructuring costs, and the consolidation of Cronos GrowCo (adding $1.0 million in Q2 2025 and $1.9 million for the six months)[51] Net Loss (Constant Currency) On a constant currency basis, Q2 2025 net loss increased to $39.8 million, and for the six months ended June 30, 2025, it rose to $32.5 million, mainly due to unrealized foreign exchange losses Net Loss (Constant Currency, Thousand Dollars) | Period | 2025 | 2024 | Change ($) | Change (%) | | :-------------------------------- | :----- | :----- | :--------- | :--------- | | Three Months Ended June 30 | (39,798) | (8,759) | (31,039) | (354) % | | Six Months Ended June 30 | (32,477) | (11,243) | (21,234) | (189) % | - The increase in net loss is primarily due to unrealized foreign exchange losses on U.S. dollar-denominated cash and short-term investments held in Canada (impacted by a stronger Canadian dollar against the U.S. dollar), partially offset by higher gross profit and lower operating expenses[52] Adjusted EBITDA (Constant Currency) On a constant currency basis, Q2 2025 Adjusted EBITDA improved to $1.6 million, and for the six months ended June 30, 2025, it improved to $3.9 million, driven by higher gross profit and lower operating expenses Adjusted EBITDA (Constant Currency, Thousand Dollars) | Period | 2025 | 2024 | Change ($) | Change (%) | | :-------------------------------- | :----- | :----- | :--------- | :--------- | | Three Months Ended June 30 | 1,587 | (11,051) | 12,638 | N/M | | Six Months Ended June 30 | 3,920 | (21,720) | 25,640 | N/M | - The improvement in Adjusted EBITDA is primarily attributed to higher gross profit and lower operating expenses (particularly reduced general and administrative expenses)[53] Cash and Cash Equivalents & Short-term Investments (Constant Currency) On a constant currency basis, total cash and short-term investments decreased 3% to $832.6 million as of June 30, 2025, primarily due to capital expenditures, share repurchases, and dividend payments Total Cash and Cash Equivalents and Short-term Investments (Constant Currency, Thousand Dollars) | Metric | As of June 30, 2025 | As of December 31, 2024 | Change ($) | Change (%) | | :------------------------------------------------ | :------------------ | :----------------- | :--------- | :--------- | | Total Cash and Cash Equivalents and Short-term Investments | 832,622 | 858,805 | (26,183) | (3) % | - The decrease is primarily due to purchases of property, plant, and equipment, repurchases of common shares, dividends paid to non-controlling interests, and tax withholdings related to equity-based compensation[54] Foreign Currency Exchange Rates This section provides spot and average foreign currency exchange rates for USD against CAD and ILS, highlighting the strengthening of the Canadian dollar against the US dollar USD to CAD Exchange Rates (C$ per $) | Exchange Rate Type | June 30, 2025 | June 30, 2024 | December 31, 2024 | | :-------- | :------------ | :------------ | :---------------- | | Spot Rate | 1.3608 | 1.3674 | 1.4351 | | Average Rate | 1.4094 | 1.3581 | N/A | USD to Israeli New Shekel Exchange Rates (ILS per $) | Exchange Rate Type | June 30, 2025 | June 30, 2024 | December 31, 2023 | | :-------- | :------------ | :------------ | :---------------- | | Spot Rate | 3.3683 | 3.7742 | 3.6526 | | Average Rate | 3.5954 | 3.6950 | N/A | Investor Relations Contact This section provides the contact information for Cronos Group's investor relations, including the contact person's name, email, and phone number Contact Information This section provides the contact information for Cronos Group's investor relations, including the contact person's name, phone, and email address - Investor Relations Contact: Harrison Aaron[56] - Email: investor.relations@thecronosgroup.com[56]